Anúncio
Anúncio

FENC

FENC logo

Fennec Pharmaceuticals Inc. Common Stock

7.75
USD
Patrocinado
+0.17
+2.18%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

7.77

+0.02
+0.32%

Relatórios de Lucros FENC

Rácio de surpresa positiva

FENC separação 15 de 33 últimas estimativas.

45%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$14.03M
/
$0.04
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+12.56%
/
-300.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+77.00%
/
-166.67%

Fennec Pharmaceuticals Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, FENC reported earnings of -0.02 USD per share (EPS) for Q3 25, beating the estimate of -0.02 USD, resulting in a 8.26% surprise. Revenue reached 12.46 milhão, compared to an expected 11.48 milhão, with a 8.54% difference. The market reacted with a +2.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of 0.04 USD, with revenue projected to reach 14.03 milhão USD, implying an diminuir of -300.00% EPS, and aumentar of 12.56% in Revenue from the last quarter.
FAQ
For Q3 2025, Fennec Pharmaceuticals Inc. Common Stock reported EPS of -$0.02, beating estimates by 8.26%, and revenue of $12.46M, 8.54% above expectations.
The stock price moved up 2.21%, changed from $7.69 before the earnings release to $7.86 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 7 analistas, Fennec Pharmaceuticals Inc. Common Stock is expected to report EPS of $0.04 and revenue of $14.03M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio